AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26771733 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (bolus plus infusion)
Number of subjects: 140
Study 26771733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 140
Study 24345886 — intervention group
Group type: EXPERIMENTAL
Intervention: 56.5 μg teriparatide
Number of subjects: 66
Study 24345886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 22652160 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin (5 mg) + Trospium Chloride (20 mg) administered 3 times a day and 4 times a day respectively in Group A
Number of subjects: 12
Study 22652160 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin (5 mg) + Solifenacin (10 mg) administered 3 times a day and once daily respectively in Group B
Number of subjects: 12
Study 19933512 — intervention group
Group type: EXPERIMENTAL
Intervention: Huffing manoeuvre before i.v. fentanyl (2.5 microg kg(‐1))
Number of subjects: 300
Study 19933512 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal breathing before i.v. fentanyl (2.5 microg kg(‐1)))
Number of subjects: 300
Study 17392649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC, 400 mg b.d.), esomeprazole (40 mg/day), amoxycillin (1 g t.d), and tinidazole (500 mg b.d.) with bovine lactoferrin (200 mg b.d)
Number of subjects: 70
Study 17392649 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate (RBC, 400 mg b.d.), esomeprazole (40 mg/day), amoxycillin (1 g t.d), and tinidazole (500 mg b.d.) without bovine lactoferrin
Number of subjects: 70
Study 16118569 — intervention group
Group type: EXPERIMENTAL
Intervention: Most active women (vigorous physical activity 10-12 months x yr) during high school and age 18-22 yr
Number of subjects: 477
Study 16118569 — intervention group
Group type: EXPERIMENTAL
Intervention: Most active women (> or = 1500 kcal x wk(‐1))
Number of subjects: 477
Study 16118569 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity during young adulthood
Number of subjects: 477
Study 14622730 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental care
Number of subjects: 19
Study 10197573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato diet (16.5 mg lycopene)
Number of subjects: 10
Study 10197573 — intervention group
Group type: COMPARATOR
Intervention: Tomato-free diet
Number of subjects: 10
Study 7767241 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly feedback with peer comparison
Number of subjects: 179
Study 1430964 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic device for carpal tunnel release
Number of subjects: 122
Study 1430964 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 122
Study 3902512 — intervention group
Group type: EXPERIMENTAL
Intervention: HTF medium
Number of subjects: 113
Study 3902512 — intervention group
Group type: COMPARATOR
Intervention: T6 medium
Number of subjects: 113
Study 30580275 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC screening participants (faecal immunochemical test: n=958; colonoscopy: n=298)
Number of subjects: 1409
Study 30580275 — intervention group
Group type: COMPARATOR
Intervention: Non-participants in CRC screening
Number of subjects: 1409
Study 30580275 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anxiety levels
Number of subjects: 1409
Study 30580275 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower anxiety levels
Number of subjects: 1409
Study 27614452 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoelectric and musical treatment group (Group 1)
Number of subjects: 174
Study 27614452 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (Group 2)
Number of subjects: 174
Study 27614452 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo group (Group 3)
Number of subjects: 174
Study 25554976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay for performance scheme
Number of subjects: 0
Study 23083636 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 141
Study 23083636 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 19280340 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy
Number of subjects: 1850
Study 19280340 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 1850
Study 18629567 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (mailed reminder, treatment guidelines, educational package)
Number of subjects: 270
Study 18629567 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 270
Study 16775668 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) 1,200 mg daily for 6 weeks, then replaced by placebo (XZK discontinued group; n = 25)
Number of subjects: 75
Study 16775668 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) 1,200 mg daily throughout the study (XZK continued group; n = 25)
Number of subjects: 75
Study 16775668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no XZK group; n = 25)
Number of subjects: 75
Study 15030293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (Zetia) as monotherapy
Number of subjects: 0
Study 15030293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe coadministered with statins (simvastatin, atorvastatin, lovastatin, or pravastatin)
Number of subjects: 0
Study 15030293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus statin coadministration
Number of subjects: 0
Study 15030293 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy
Number of subjects: 0
Study 10944137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) using cyclophosphamide, carmustine, and etoposide (CBV regimen) followed by stem-cell transplantation
Number of subjects: 236
Study 10944137 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy (ifosfamide plus etoposide, asparaginase, and cytarabine)
Number of subjects: 236
Study 10944137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT)
Number of subjects: 236
Study 10944137 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 236
Study 8596127 — intervention group
Group type: EXPERIMENTAL
Intervention: co-amoxiclav (amoxicillin 875 mg + clavulanic acid 125 mg) twice daily for 10 days
Number of subjects: 218
Study 8596127 — intervention group
Group type: COMPARATOR
Intervention: cefixime (400 mg) once daily for 10 days
Number of subjects: 218
Study 8596127 — intervention group
Group type: COMPARATOR
Intervention: ciprofloxacin (500 mg) twice daily for 10 days
Number of subjects: 218
Study 2172578 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrich (12.8 g of dietary fiber per 1000 kcal)
Number of subjects: 28
Study 2172578 — intervention group
Group type: COMPARATOR
Intervention: Ensure (fiber-free)
Number of subjects: 28
Study 365212 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP
Number of subjects: 250
Study 365212 — intervention group
Group type: COMPARATOR
Intervention: BARTS III
Number of subjects: 250
Study 31857621 — intervention group
Group type: EXPERIMENTAL
Intervention: Kazakh students
Number of subjects: 7096
Study 31857621 — intervention group
Group type: EXPERIMENTAL
Intervention: Uygur students
Number of subjects: 7096
Study 31857621 — intervention group
Group type: EXPERIMENTAL
Intervention: Han students
Number of subjects: 7096
Study 31857621 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight, overweight, and obesity groups
Number of subjects: 7096
Study 27853926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS over the left dorsolateral prefrontal cortex
Number of subjects: 15
Study 27853926 — intervention group
Group type: COMPARATOR
Intervention: Sham protocol
Number of subjects: 15
Study 26445227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Iodine-125 brachytherapy and DP regimen (docetaxel 60 mg/m²/cisplatin 75 mg/m²)
Number of subjects: 52
Study 26445227 — intervention group
Group type: COMPARATOR
Intervention: DP chemotherapy
Number of subjects: 52
Study 23570818 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy challenge intervention
Number of subjects: 96
Study 23570818 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study 21226782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pros enhancement intervention
Number of subjects: 1436
Study 21226782 — intervention group
Group type: COMPARATOR
Intervention: Education session (control)
Number of subjects: 1436
Study 18663661 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 400
Study 18663661 — intervention group
Group type: COMPARATOR
Intervention: Non-CPAP treatment
Number of subjects: 400
Study 17229894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of DHA
Number of subjects: 116
Study 17229894 — intervention group
Group type: COMPARATOR
Intervention: 1252 mg of DHA + EPA
Number of subjects: 116
Study 14637268 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate 1000 mg intravenously over 1 h
Number of subjects: 34
Study 14637268 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C 1000 mg intravenously over 1 h
Number of subjects: 34
Study 10618558 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranilast (300 and 450 mg twice daily for 1 or 3 months)
Number of subjects: 11500
Study 10618558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11500
Study 9414347 — intervention group
Group type: EXPERIMENTAL
Intervention: Different rifle designs
Number of subjects: 12
Study 9414347 — intervention group
Group type: EXPERIMENTAL
Intervention: Aiming stability
Number of subjects: 12
Study 9414347 — intervention group
Group type: EXPERIMENTAL
Intervention: Aiming fluctuations
Number of subjects: 12
Study 8500334 — intervention group
Group type: EXPERIMENTAL
Intervention: trifluridine
Number of subjects: 74
Study 8500334 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone
Number of subjects: 74
Study 8500334 — intervention group
Group type: EXPERIMENTAL
Intervention: artificial tears
Number of subjects: 74
Study 2834500 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabi 2165 (n = 40): 2,500 U anti‐Xa preoperatively and evening of operation and 2,500 U anti‐Xa morning and evening daily up to the 9th or 10th day postoperatively
Number of subjects: 80
Study 2834500 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (n = 40): 3,750 U preoperatively and then 8 hourly, adjusted with thrombin time and cephalin + activator time, daily up to the 9th or 10th day
Number of subjects: 80
Study 2834500 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tolerance evaluated from hemoglobin and hematocrit values, intra‐ and post‐operative bleeding, operation wound hematoma, and injection site
Number of subjects: 80
Study 30031988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 49
Study 30031988 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 49
Study 27023086 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α inhibitors
Number of subjects: 0
Study 25057084 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 maintenance chemotherapy (40 mg/m², twice daily for 14 days; 21 days for a treatment cycle)
Number of subjects: 60
Study 25057084 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 maintenance chemotherapy
Number of subjects: 60
Study 25057084 — intervention group
Group type: COMPARATOR
Intervention: Optimal supportive care
Number of subjects: 60
Study 22049088 — intervention group
Group type: EXPERIMENTAL
Intervention: Received a letter informing them that the results of the trial could be consulted on a specific website.
Number of subjects: 107
Study 22049088 — intervention group
Group type: COMPARATOR
Intervention: Did not receive a letter informing them about the trial results.
Number of subjects: 107
Study 21170108 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (lamivudine 100 mg/d for 32 weeks + interferon alpha 2b 5 million units every other day for 24 weeks)
Number of subjects: 225
Study 21170108 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine monotherapy (100 mg/d for 48 weeks)
Number of subjects: 225
Study 21170108 — intervention group
Group type: COMPARATOR
Intervention: Interferon monotherapy (5 million units every other day for 24 weeks)
Number of subjects: 225
Study 15732268 — intervention group
Group type: EXPERIMENTAL
Intervention: Story Memory Technique (SMT)
Number of subjects: 29
Study 15732268 — intervention group
Group type: COMPARATOR
Intervention: Memory exercises (Control)
Number of subjects: 29
Study 12957262 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy delay of 0-9 days
Number of subjects: 1226
Study 12957262 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy delay of 10+ days
Number of subjects: 1226
Study 9888081 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-site group (mitomycin-C trabeculectomy with phacoemulsification through a separate incision)
Number of subjects: 76
Study 9888081 — intervention group
Group type: COMPARATOR
Intervention: 1-site group (mitomycin-C trabeculectomy with phacoemulsification through the same incision)
Number of subjects: 76
Study 9888081 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-site group
Number of subjects: 76
Study 9888081 — intervention group
Group type: COMPARATOR
Intervention: 1-site group
Number of subjects: 76
Study 9034556 — intervention group
Group type: EXPERIMENTAL
Intervention: Saruplase (80 mg)
Number of subjects: 230
Study 9034556 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (3 million units)
Number of subjects: 230
Study 1848607 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium‐201‐diethyldithiocarbamate SPECT imaging within 24 hours after stroke
Number of subjects: 26
Study 1848607 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium‐201‐diethyldithiocarbamate SPECT imaging at 2 weeks after stroke
Number of subjects: 26
Study 1848607 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium‐201‐diethyldithiocarbamate SPECT imaging at 6 months after stroke
Number of subjects: 26
Study 1848607 — intervention group
Group type: COMPARATOR
Intervention: Calcium‐entry blocker flunarizine (random treatment)
Number of subjects: 26
Study 6391611 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 per cent silver sulfadiazine plus 0.2 per cent chlorhexidine digluconate (Silvazine)
Number of subjects: 121
Study 6391611 — intervention group
Group type: COMPARATOR
Intervention: 1 per cent silver sulfadiazine (Flamazine)
Number of subjects: 121
Study 31256255 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent anastomosis (SA)
Number of subjects: 60
Study 31256255 — intervention group
Group type: COMPARATOR
Intervention: Quality of life (QOL) assessment
Number of subjects: 60
Study 30309994 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA-based outpatient care in addition to usual care
Number of subjects: 0
Study 30309994 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study 26609642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutomesh TUTOGEN biological prosthesis reinforcement parietal herniorrhaphy (Group B)
Number of subjects: 134
Study 26609642 — intervention group
Group type: COMPARATOR
Intervention: Simple parietal herniorrhaphy without prosthetic reinforcement (Group A)
Number of subjects: 134
Study 25275513 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA neutralization
Number of subjects: 208
Study 25275513 — intervention group
Group type: EXPERIMENTAL
Intervention: α-defensins and secretory leukocyte protease inhibitor (SLPI) levels
Number of subjects: 208
Study 22510426 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weekly individual child CBT sessions and 2 parent sessions
Number of subjects: 204
Study 22510426 — intervention group
Group type: COMPARATOR
Intervention: minimal information
Number of subjects: 204
Study 19460773 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (5 microg/kg, twice a day for 3 days)
Number of subjects: 74
Study 17515447 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 13
Study 17515447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15300574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal COX‐2 assay
Number of subjects: 51
Study 15300574 — intervention group
Group type: COMPARATOR
Intervention: Fecal CEA assay
Number of subjects: 51
Study 11594100 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive therapeutic message audiotape
Number of subjects: 27
Study 11594100 — intervention group
Group type: COMPARATOR
Intervention: Blank (Controls)
Number of subjects: 27
Study 9791046 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (0, 2 and 4 pmol.min‐1.kg‐1 for 1 h each)
Number of subjects: 6
Study 9791046 — intervention group
Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (0, 2 and 4 pmol.min‐1.kg‐1 for 1 h each)
Number of subjects: 6
Study 9791046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7988254 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 328
Study 7988254 — intervention group
Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 328
Study 2729751 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline after resistive breathing
Number of subjects: 8
Study 2729751 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory flow resistive loads (4.5 to 27.0 cm H2O/L/s)
Number of subjects: 8
Study 30486858 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI)
Number of subjects: 2550
Study 30486858 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2550
Study 28426123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg daily for 12 weeks)
Number of subjects: 41
Study 28426123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (after randomization)
Number of subjects: 41
Study 28426123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after randomization)
Number of subjects: 41
Study 28426123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (overall)
Number of subjects: 41
Study 28426123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (in patients with elevated baseline AFP)
Number of subjects: 41
Study 25991385 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles
Number of subjects: 70
Study 25991385 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot walking
Number of subjects: 70
Study 25991385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility shoe
Number of subjects: 70
Study 25991385 — intervention group
Group type: COMPARATOR
Intervention: Control shoe
Number of subjects: 70
Study 25991385 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical wedge
Number of subjects: 70
Study 25991385 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported wedge
Number of subjects: 70
Study 23777311 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER)
Number of subjects: 184
Study 21832305 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+CAFF (Carbohydrate + Caffeine)
Number of subjects: 6
Study 21832305 — intervention group
Group type: COMPARATOR
Intervention: CHO (Carbohydrate)
Number of subjects: 6
Study 21832305 — intervention group
Group type: COMPARATOR
Intervention: WAT (Water)
Number of subjects: 6
Study 19637480 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone rubber impression
Number of subjects: 389
Study 19637480 — intervention group
Group type: COMPARATOR
Intervention: Agar/alginate combination impression
Number of subjects: 389
Study 16946030 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min exercise at 70% peak oxygen consumption
Number of subjects: 15
Study 16946030 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min exercise at 70% peak oxygen consumption
Number of subjects: 15
Study 16946030 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 min exercise at 70% peak oxygen consumption
Number of subjects: 15
Study 16946030 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 15
Study 16946030 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 15
Study 16946030 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise duration
Number of subjects: 15
Study 16946030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 15
Study 14691688 — intervention group
Group type: EXPERIMENTAL
Intervention: desferrioxamine
Number of subjects: 22
Study 14691688 — intervention group
Group type: EXPERIMENTAL
Intervention: deferiprone (L1)
Number of subjects: 22
Study 14691688 — intervention group
Group type: COMPARATOR
Intervention: baseline
Number of subjects: 22
Study 14691688 — intervention group
Group type: COMPARATOR
Intervention: 1 year follow up
Number of subjects: 22
Study 14691688 — intervention group
Group type: COMPARATOR
Intervention: 3 year follow up
Number of subjects: 22
Study 11531864 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal (TEP) repair
Number of subjects: 200
Study 11531864 — intervention group
Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 200
Study 9037444 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg once daily) alone (group A) for 4 weeks
Number of subjects: 52
Study 9037444 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg once daily) + tripotassium dicitrato bismuthate (TDB; 240 mg bid) for 4 weeks (group B)
Number of subjects: 52
Study 9037444 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg bid) for 2 weeks + amoxicillin (1 g bid only 2nd week) (group A)
Number of subjects: 52
Study 9037444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) monotherapy for 4 weeks (group B)
Number of subjects: 52
Study 8100221 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral (10 mg) and i.m. (0.5 mg) medication
Number of subjects: 24
Study 8100221 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral dosing (5 mg on trial days 1, 2, 3, 5, 7, 9, 11 and 13)
Number of subjects: 24
Study 8100221 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral dosing (5 mg on trial days 5 to 14) with initial i.m. loading doses (0.5 mg i.m. on trial days 1, 2 and 4)
Number of subjects: 24
Study 8100221 — intervention group
Group type: COMPARATOR
Intervention: i.m. administration
Number of subjects: 24